Pharma Exclusives Pressreleases
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
Thursday, April 24, 2025Zealand Pharma ASa biotechnology company focused on the discovery and development of innovative peptidebased medicines today announced that the first participant has been enrolled in ZUPREME a Phase b trial in people with overweight or obesity
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
Wednesday, April 23, 2025Rocheannounced today the introduction of its innovative Chest Pain Triage algorithm as part of the navify Algorithm Suite This groundbreaking algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome ACS
Eleva Publishes Evidence of Immunomodulation and Neuroprotection Using its Factor H Biological Therapy in Preclinical Dry AMD Study
Tuesday, April 15, 2025Eleva a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform announced today the publication of new data on its lead pipeline asset Factor H CPV in the peerreviewed Journal of Neuroinflam...
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
Wednesday, April 02, 2025Boehringer Ingelheim today announced a continued rise in the number of patients it reached million in up from the previous year Development of its current product pipeline is well on track as the company prepares multiple new product launches star...
First ISCC Plus Certifications Pave the Way for Renewable Plastics at Sartorius
Tuesday, April 01, 2025The life science group Sartorius has earned its first certificates from the International Sustainability and Carbon Certification ISCC for its production sites in Aubagne France and Stonehouse UK Further plants in Germany and Finland are to follow
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
Tuesday, April 01, 2025GRI Bio Inca biotechnology company advancing an innovative pipeline of Natural Killer T NKT cell modulators for the treatment of inflammatory fibrotic and autoimmune diseases today announced the granting of two global patents
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
Tuesday, April 01, 2025Positive results from the PURSUIT Phase IIb trial for AstraZenecas AZD demonstrated a statistically significant lowdensity lipoprotein cholesterol LDLC reduction when administered on top of standardofcare statin therapy as compared with placebo
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
Tuesday, April 01, 2025Eisai Co Ltdand Biogen Inc announced today an update on the ongoing regulatory review of the Marketing Authorization Application
Lonza Implements its Simplified and Streamlined Operating Model
Tuesday, April 01, 2025Lonza has announced that its new simplified and streamlined operating model is effective from today At its Investor Update in December Lonza announced its new One Lonza vision and strategy centered around the Lonza Engine which brings together the c...
Ryvu Therapeutics Announces Dosing of the First Patient in the JASPIS-01 Phase II Study of Dapolsertib (MEN1703/SEL24) for the Treatment of r/r DLBCL
Thursday, March 27, 2025Ryvu Therapeutics a clinicalstage drug discovery and development company focusing on novel therapies that address emerging targets in oncology announced today that the first patient has been dosed in the JASPIS study
